9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one Hydrate Hydrochloride

Base Information

• Chemical Name: 9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one Hydrate Hydrochloride
• CAS No.: 103639-04-9
• Molecular Formula: C18H24ClN3O3
• Molecular Weight: 365.85
• Hs Code.: 2933290000
• European Community (EC) Number: 619-448-9
• NCI Thesaurus Code: C48007
• RXCUI: 203148
• ChEMBL ID: CHEMBL1487310
• Mol file: 103639-04-9.mol

Synonyms:9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one Hydrate Hydrochloride;Zofran;99614-01-4;ONDANSETRON HYDROCHLORIDE;128061-08-5;4H-Carbazol-4-one, 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-, hydrochloride, hydrate (1:1:1);9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one;hydrate;hydrochloride;SN 307;once-daily ondansetron;MLS001074357;SCHEMBL7217409;CHEMBL1487310;SMR000674605;9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-1,2,3,9-tetrahydro-4H-carbazol-4-one hydrochloride hydrate

Chemical Property of 9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one Hydrate Hydrochloride

Chemical Property:

• Appearance/Colour: White crystal powder
• Vapor Pressure: 1.47E-12mmHg at 25°C
• Melting Point: 231-232oC
• Boiling Point: 546 °C at 760 mmHg
• Flash Point: 284 °C
• PSA: 58.28000
• Density: 1.27 g/cm³
• LogP: 3.80190
• Storage Temp.: −20°C
• Solubility.: H2O: >5mg/mL
• Hydrogen Bond Donor Count: 2
• Hydrogen Bond Acceptor Count: 3
• Rotatable Bond Count: 2
• Exact Mass: 347.1400546
• Heavy Atom Count: 24
• Complexity: 440

Purity/Quality:

99% ,99.9%, ^*data from raw suppliers

Ondansetron, Hydrochloride ^*data from reagent suppliers

Safty Information:

• Pictogram(s): T,Xi
• Hazard Codes: T,Xi
• Statements: 25-36/37/38-50/53-41
• Safety Statements: 45-37/39-26-61-39

MSDS Files:

SDS file from LookChem

Total 1 MSDS from other Authors

Useful:

• Canonical SMILES: CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C.O.Cl
• Recent EU Clinical Trials: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Tolerability of AD04 (Ondansetron) in Adults with Alcohol Use Disorder (AUD) and Selected Polymorphisms in the Serotonin Transporter and Receptor Genes (ONWARD)
• Description: Ondansetron hydrochloride is a selective 5HT3-antagonist approved for the management of nausea and vomiting induced by cancer chemotherapy and radiotherapy. It is reported to have a superior side-effect profile compared with metoclopramide, representing an important advance in the treatment of nausea and vomiting associated with chemotherapy. Ondansetron hydrochloride is the first specific 5HT3-antagonist to reach the market. It is also under investigation for a number of other indications, including anxiety and schizophrenia.
• Uses: Antiemetic;Serotonergic receptor antagonist A serotonin type 3 receptor antagonist. These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements. Ondansetron hydrochloride dihydrate has been used as a 5-HT3 antagonist to attenuate rostro ventromedial medulla (RVM)/cholecystokinin (CCK)-induced mechanical hypersensitivity and to block the effects of trichostatin A (TSA) on 5-HT3 protein.
• Therapeutic Function: Serotonin antagonist